MedPharm set to launch First-of-Its kind Cannabis-based Clinical Trial in Alzheimer MedPharm Holdings, an acquisition target of Medicine Man Technologies (OTCQX: MDCL), is all set to launch a landmark, double-blind, placebo controlled clinical trial which will evaluate the effect of cannabis on patients with Dementia and...
Lexicon Pharmaceuticals (NASDAQ: LXRX), a biopharmaceutical company leveraging its proprietary Genome5000™ program to develop therapeutics for the treatment of disease such as diabetes, metabolism, oncology and neuropathic pain, announced that the Food and Drug Administration (FDA) has reiterated its rejection of the Company’s New Drug...
Profound Medical Corp (NASDAQ: PROF), a medical technology Company that offers magnetic resonance guided ablation procedures, announced the approval of its TULSA-PRO® system for the ablation of low to intermediate risk organ-confined prostate cancer by Heath Canada. The Company develops innovative, customizable, incision-free and radiation free...
Holiday season beings cheers to not only consumers but also to Companies, which try to make the most of the season by offering products, services and discounts to entice customers to make a purchase. The increase in disposable incomes and a consequent rise in spending...
Axcella Health (NASDAQ: AXLA), a biotechnology Company focussed on leveraging the power of Endogenous Metabolic Modulators, announced the issuance of a third EMM-related patent covering an array of EMM compositions, including AXA1125 and AXA1957, the company’s product candidates for non-alcoholic steatohepatitis (NASH). The patent broadens...
Gout is a form of inflammatory Arthritis caused by high levels of uric acid in the blood, and is characterised by the formation of needle-like crystals in the joints that cause pain, tenderness and swelling. The disease manifests in four stages namely Asymptomatic hyperuricemia in...
Axovant Gene Therapies (NASDAQ: AXGT) announced the grant of an Orphan Drug Designation for AXO-AAV-GM1, the Company’s investigational gene therapy for the treatment of GM1 gangliosidosis. AXO-AAV-GM1 is capable of restoring the β-galactosidase enzyme activity by delivering a functional copy of the dysfunctional GLB1 gene,...
Foamix and Menlo Therapeutics have signed a definitive merger agreement to form a biopharmaceutical Company focused on dermatological conditions. The combined entity will have a robust portfolio of diversified candidates, including an approved product and three late-stage clinical candidates. Foamix’s AMZEEQ™ (minocycline) topical foam, 4%, recently...
Obseva (NASDAQ: OBSV), a biopharmaceutical Company focused on women’s reproductive health announced the discontinuation of nolasiban (OBE001), an oral oxytocin receptor antagonist intended for women undergoing embryo transfer (ET) following in-vitro fertilization (IVF). The candidate, though well-tolerated, failed to meet the primary endpoint of an increase...
Conformis Inc (NASDAQ: CFMS), a medical technology company dealing in Knee and Joint replacements, has announced the clearance of its next generation Conformis Hip System by the FDA. The Company’s leading-edge patient-specific arthroplasty joint replacement implants, moulded to suit each patient’s unique anatomy, are developed...
